Sanofi: Tolebrutinib For NrSPMS Meets Primary Goal In HERCULES Trial; Fails In GEMINI Trial For RMS
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – French drug major Sanofi (SNYNF, SNY) announced Monday that its oral brain-penetrant Bruton’s tyrosine kinase or BTK inhibitor Tolebrutinib, in the HERCULES phase 3 study, met the primary endpoint in delaying time to onset of confirmed disability progression in people
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1500340373-9a9166e04b064f1d926066341a5e27f8.jpg "Next Fed Meeting: When It Is In September and What To Expect")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1371757399-3329dac503a74576a455122fc2b08246.jpg "<div>9 Major Medicare Changes for 2025 and How They'll Impact Your Coverage</div>")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1064987572-1a79077cb179458dbbcecc5ac1b660df.jpg "Average Equity In U.S. Homes: Overview, FAQs")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-769720227_2400a-31d6e8ea286f4dea9c854eaf18af463c.jpg "Planning for Retirement? Start With These 5 Steps")